Global DNA Repair Drugs Market Analysis 2024 – Estimated Market Size And Key Drivers| Pfizer Inc., Johnson & Johnson Private Limited, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company

The DNA Repair Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The DNA Repair Drugs Market:
https://www.thebusinessresearchcompany.com/report/dna-repair-drugs-global-market-report

According to The Business Research Company’s DNA Repair Drugs Global Market Report 2024, The dna repair drugs market size has grown exponentially in recent years. It will grow from $8.93 billion in 2023 to $10.89 billion in 2024 at a compound annual growth rate (CAGR) of 21.9%. The growth in the historic period can be attributed to increasing understanding of dna repair mechanisms, growth in cancer research, evolving regulatory landscape for pharmaceuticals, rising prevalence of genetic disorders, expansion of personalized medicine.

The dna repair drugs market size is expected to see exponential growth in the next few years. It will grow to $22.72 billion in 2028 at a compound annual growth rate (CAGR) of 20.2%. The growth in the forecast period can be attributed to development of targeted therapies for dna repair, growing focus on precision medicine, rise in the aging population, increased funding for dna repair drug development. Major trends in the forecast period include integration of artificial intelligence in drug discovery for dna repair, development of combination therapies targeting dna repair pathways, emphasis on gene editing technologies, personalized treatment regimens based on dna repair profiles, rise in clinical trials for dna repair drugs.

The rising prevalence of cancer is expected to propel the growth of the DNA repair drug market going forward. Cancer is a category of illness that develops in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. The surge in the prevalence of cancer is driven mainly by smoking, radiation, cancer-causing substances (carcinogens), obesity, and gene mutations. Cancer is prevented by interfering with DNA’s ability to fix itself, causing cancerous cells to stop replicating and die. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase compared to more than 1.8 million new cancer cases diagnosed in 2020. Therefore, the rising prevalence of cancer is driving the growth of the DNA repair drug market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12200&type=smp

The dna repair drugs market covered in this report is segmented –

1) By Drug Type: Olaparib, Rucaparib, Niraparib, Talazoparib, Other Drugs
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
3) By Application: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Other Applications

Product innovation is a key trend gaining popularity in the DNA repair drug market. Major companies operating in the DNA repair drugs market are developing innovative products to sustain their position in the market. For instance, in June 2023, AstraZeneca plc, a UK-based biopharmaceutical company, received approval for Lynparza plus abiraterone in the United States to treat BRCA-mutated metastatic castration-resistant prostate cancer. Lynparza (olaparib) is the first PARP inhibitor of its kind and the first targeted drug to block the DNA damage response (DDR) in cells or tumors without HRR (homologous recombination repair).

The dna repair drugs market report table of contents includes:

1. Executive Summary
2.DNA Repair Drugs Market Characteristics
3. DNA Repair Drugs Market Trends And Strategies
4. DNA Repair Drugs I mpact Of Market analysis
5. DNA Repair Drugs Market Size And Growth
6. DNA Repair Drugs Segmentation
7. DNA Repair Drugs Regional And Country Analysis
.
.
.
27.DNA Repair Drugs Competitive Landscape And Company Profiles
28.DNA Repair Drugs Key Mergers And Acquisitions
29.DNA Repair Drugs Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Pfizer Inc.
• Johnson & Johnson Private Limited
• AbbVie Inc.
• Bayer AG
• Novartis AG,
• Bristol-Myers Squibb Company

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model